
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
S
Cover
almost 14 years ago
Country Report: Australiaalmost 14 years ago
Turkey: A Promise Restored?almost 14 years ago
NHTSA Addresses "Drugged Driving"almost 14 years ago
Fortuity and the First Amendmentalmost 14 years ago
Oncology: Pathways to Progressalmost 14 years ago
Pharmaceutical Executive Digital Edition - February 2013





